Sign in or create an account to add this stock to your watchlist.
About Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing and commercializing pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric disorders. Its product candidates include ZYN002, which completed Phase II clinical trial for pediatric and adolescent patients with fragile X syndrome, pediatric and adolescent patients with developmental and epileptic encephalopathies, and adult patients with refractory epileptic focal seizures; and ZYN001 that is in Phase I clinical trial to treat Tourette syndrome. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Devon, Pennsylvania.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ZYNE
CUSIPN/A
Phone484-581-7505
Debt
Debt-to-Equity RatioN/A
Current Ratio6.51
Quick Ratio6.51
Price-To-Earnings
Trailing P/E Ratio-4.15
Forward P/E Ratio-3.51
P/E GrowthN/A
Sales & Book Value
Annual Sales$10,000.00
Price / Sales13,939.68
Cash FlowN/A
Price / CashN/A
Book Value$3.71 per share
Price / Book2.77
Profitability
EPS (Most Recent Fiscal Year)($2.48)
Net Income$-32,010,000.00
Net MarginsN/A
Return on Equity-59.98%
Return on Assets-52.73%
Miscellaneous
Employees22
Outstanding Shares13,560,000
Zynerba Pharmaceuticals (NASDAQ:ZYNE) Frequently Asked Questions
What is Zynerba Pharmaceuticals' stock symbol?
Zynerba Pharmaceuticals trades on the NASDAQ under the ticker symbol "ZYNE."
How were Zynerba Pharmaceuticals' earnings last quarter?
Zynerba Pharmaceuticals (NASDAQ:ZYNE) announced its earnings results on Tuesday, May, 8th. The company reported ($0.91) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.68) by $0.23. View Zynerba Pharmaceuticals' Earnings History.
What price target have analysts set for ZYNE?
11 Wall Street analysts have issued 12 month price objectives for Zynerba Pharmaceuticals' shares. Their predictions range from $7.00 to $32.00. On average, they expect Zynerba Pharmaceuticals' stock price to reach $18.45 in the next twelve months. View Analyst Ratings for Zynerba Pharmaceuticals.
What are Wall Street analysts saying about Zynerba Pharmaceuticals stock?
Here are some recent quotes from research analysts about Zynerba Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates which are in clinical trial stage include ZYN002 and ZYN001 synthetic transdermal cannabinoid therapeutics for indications including refractory epilepsy, Fragile X syndrome, osteoarthritis, fibromyalgia and peripheral neuropathic pain. Zynerba Pharmaceuticals, Inc. is headquartered in Devon, Pennsylvania. " (3/15/2018)
- 2. Cantor Fitzgerald analysts commented, "Encouraging, but Early. In our view, the effect sizes and statistical significant have been strongly encouraging for the small and exploratory Phase 2 study. Achieving 46% reduction (p<0.0001) across the primary endpoint of Anxiety, Depression, and Mood Scale (ADAMS), ZYN002 also has demonstrated clinically meaningful activity across domains of the disease as measured by Aberrant Behavior Checklist – FXS (ABC-FXS)."" (9/28/2017)
- 3. Maxim Group analysts commented, "Zynerba announced the completion of target pediatric patient enrollment (n=16, ages from 6 – 17 years old) in the Phase II FAB-C (Treatment of Fragile X Syndrome Anxiety and Behavioral Challenges with CBD) study to evaluate ZYN002, Zynerba’s cannabidiol (CBD) gel in children with Fragile X syndrome (FXS)." (6/8/2017)
Who are some of Zynerba Pharmaceuticals' key competitors?
Some companies that are related to Zynerba Pharmaceuticals include TiGenix (TIG), Progenics Pharmaceuticals (PGNX), Insys Therapeutics (INSY), Achillion Pharmaceuticals (ACHN), Evelo Biosciences (EVLO), Isotechnika Pharma (AUPH), Zealand Pharma (ZEAL), Cytokinetics (CYTK), ObsEva (OBSV), Depomed (DEPO), Concert Pharmaceuticals (CNCE), Dermira (DERM), Innate Pharma (IPHYF), Mersana Therapeutics (MRSN) and Zymeworks (ZYME).
Who are Zynerba Pharmaceuticals' key executives?
Zynerba Pharmaceuticals' management team includes the folowing people:
- Mr. Armando Anido MBA, Chairman and Chief Exec. Officer (Age 60)
- Ms. Terri B. Sebree, Pres (Age 60)
- Mr. James E. Fickenscher, Chief Financial Officer and VP of Corp. Devel. (Age 54)
- Mr. William C. Roberts, VP of Investor Relations & Corp. Communications (Age 49)
- Ms. Suzanne M. Hanlon, VP of HR, Gen. Counsel and Sec. (Age 61)
When did Zynerba Pharmaceuticals IPO?
(ZYNE) raised $42 million in an IPO on Wednesday, August 5th 2015. The company issued 3,000,000 shares at $13.00-$15.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity and Oppenheimer & Co. were co-managers.
Has Zynerba Pharmaceuticals been receiving favorable news coverage?
Media coverage about ZYNE stock has been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Zynerba Pharmaceuticals earned a media sentiment score of 0.18 on Accern's scale. They also assigned news articles about the company an impact score of 44.79 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future.
Who are Zynerba Pharmaceuticals' major shareholders?
Zynerba Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.27%), Northern Trust Corp (1.23%), Millennium Management LLC (0.77%), A.R.T. Advisors LLC (0.64%), Wells Fargo & Company MN (0.31%) and Alps Advisors Inc. (0.27%). Company insiders that own Zynerba Pharmaceuticals stock include Armando Anido, James E Fickenscher, Michael Rapp and Suzanne M Hanlon. View Institutional Ownership Trends for Zynerba Pharmaceuticals.
Which major investors are buying Zynerba Pharmaceuticals stock?
ZYNE stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, BlackRock Inc., Northern Trust Corp, A.R.T. Advisors LLC, Alps Advisors Inc., JPMorgan Chase & Co. and Wells Fargo & Company MN. Company insiders that have bought Zynerba Pharmaceuticals stock in the last two years include Armando Anido, James E Fickenscher and Michael Rapp. View Insider Buying and Selling for Zynerba Pharmaceuticals.
How do I buy shares of Zynerba Pharmaceuticals?
Shares of ZYNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Zynerba Pharmaceuticals' stock price today?
One share of ZYNE stock can currently be purchased for approximately $10.28.
How big of a company is Zynerba Pharmaceuticals?
Zynerba Pharmaceuticals has a market capitalization of $139.41 million and generates $10,000.00 in revenue each year. The company earns $-32,010,000.00 in net income (profit) each year or ($2.48) on an earnings per share basis. Zynerba Pharmaceuticals employs 22 workers across the globe.
How can I contact Zynerba Pharmaceuticals?
Zynerba Pharmaceuticals' mailing address is 80 W. LANCASTER AVENUE SUITE 300, DEVON PA, 19333. The company can be reached via phone at 484-581-7505 or via email at [email protected]
MarketBeat Community Rating for Zynerba Pharmaceuticals (ZYNE)
MarketBeat's community ratings are surveys of what our community members think about Zynerba Pharmaceuticals and other stocks. Vote "Outperform" if you believe ZYNE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZYNE will underperform the S&P 500 over the long term. You may vote once every thirty days.
Zynerba Pharmaceuticals (NASDAQ:ZYNE) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
11 Wall Street analysts have issued ratings and price targets for Zynerba Pharmaceuticals in the last 12 months. Their average twelve-month price target is $18.45, suggesting that the stock has a possible upside of 79.47%. The high price target for ZYNE is $32.00 and the low price target for ZYNE is $7.00. There are currently 4 hold ratings and 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Hold |
| Consensus Rating Score: | 2.64 | 2.64 | 2.64 | 2.44 |
| Ratings Breakdown: | 0 Sell Rating(s)
4 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
4 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
4 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
5 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $18.45 | $18.45 | $18.15 | $15.1250 |
| Price Target Upside: | 79.47% upside | 81.42% upside | 50.12% upside | 12.54% upside |
Zynerba Pharmaceuticals (NASDAQ:ZYNE) Consensus Price Target History
Zynerba Pharmaceuticals (NASDAQ:ZYNE) Analyst Ratings History
Show:
(Data available from 5/20/2016 forward)
Zynerba Pharmaceuticals (NASDAQ:ZYNE) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Zynerba Pharmaceuticals (NASDAQ ZYNE) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 12.67%
Institutional Ownership Percentage: 28.94%
Zynerba Pharmaceuticals (NASDAQ ZYNE) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/2/2018 | Michael Rapp | Major Shareholder | Buy | 15,000 | $10.46 | $156,900.00 | |  |
| 3/22/2018 | Michael Rapp | Major Shareholder | Buy | 10,000 | $9.28 | $92,800.00 | | |
| 1/2/2018 | Michael Rapp | Major Shareholder | Buy | 15,000 | $12.99 | $194,850.00 | | |
| 10/23/2017 | Michael Rapp | Major Shareholder | Buy | 25,745 | $9.94 | $255,905.30 | | |
| 10/19/2017 | Michael Rapp | Major Shareholder | Buy | 44,255 | $9.59 | $424,405.45 | | |
| 5/15/2017 | Armando Anido | Chairman | Buy | 5,000 | $19.70 | $98,500.00 | 336,012 | |
| 5/12/2017 | James E Fickenscher | CFO | Buy | 5,200 | $19.82 | $103,064.00 | 12,200 | |
| 12/29/2016 | Michael Rapp | Major Shareholder | Buy | 10,000 | $15.85 | $158,500.00 | 1,354,115 | |
| 12/7/2016 | James E Fickenscher | CFO | Buy | 7,000 | $14.08 | $98,560.00 | 3,000 | |
| 8/16/2016 | Suzanne M Hanlon | Insider | Sell | 3,000 | $10.53 | $31,590.00 | 39,893 | |
(Data available from 1/1/2013 forward)
Zynerba Pharmaceuticals (NASDAQ ZYNE) News Headlines
| Source: |
|
Zynerba Pharmaceuticals (NASDAQ:ZYNE) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Zynerba Pharmaceuticals (NASDAQ:ZYNE) Income Statement, Balance Sheet and Cash Flow Statement
Zynerba Pharmaceuticals (NASDAQ ZYNE) Stock Chart for Sunday, May, 20, 2018
Loading chart…
